Kailera Therapeutics Reports Positive Phase 3 Trial Results for Obesity Treatment

Kailera Therapeutics (NASDAQ:KLRA) announced positive results from two Phase 3 trials of its oral GLP-1 receptor agonist, KAI-7535. The drug showed significant weight loss in obesity patients and improved HbA1c levels for type 2 diabetes sufferers, with no major safety concerns observed.

By Maham Fatima Fri, July 10, 2026 at 4:58 PM GMT+3 2 min read · Yahoo Finance · July 10, 2026, 13:58 UTC

Tickers: $KLRA

Topics: biotechnology GLP-1 agonist IPO stock obesity treatment

Read the full article at Yahoo Finance

More World news

Nvidia CEO Jensen Huang Resigns Amid Investigation and Personal Allegations Motley Fool · November 12, 2026, 17:20 UTC
Argus Research Upgrades Republic Services to Buy Seeking Alpha · November 12, 2026, 17:16 UTC
Moderna Shares Decline Following Analyst Day Projections and Future Cost Concerns Motley Fool · November 12, 2026, 17:13 UTC
United Airlines Restricts AI Agent Access to Booking Systems Due to Cybersecurity and Regulatory Concerns TechCrunch · November 12, 2026, 17:17 UTC
Global Payments Shares Drop 12% Following Reports Private Equity Firms Abandoned Takeover Bid Seeking Alpha · November 12, 2026, 17:14 UTC
Nvidia Appoints Colette Kress as Interim CEO Following Jensen Huang's Resignation CNBC · November 12, 2026, 16:59 UTC
Brookfield Corporation Reports Strong Third Quarter Earnings Growth and Increased Share Buybacks Motley Fool · November 12, 2026, 17:08 UTC
Franco-Nevada Reports Q3 2026 Revenue Growth Driven by Higher Gold and Oil Prices Motley Fool · November 12, 2026, 17:10 UTC
Stratasys Reports Q3 2026 Revenue Growth Driven by Aerospace and Defense Demand Motley Fool · November 12, 2026, 17:11 UTC
Jim Cramer Advises Profit-Taking Following Jensen Huang's Resignation at Nvidia CNBC · November 12, 2026, 16:59 UTC